Resistance, fitness, adherence, and potency: mapping the paths to virologic failure

Editorial

M Markowitz. JAMA. 2000.

. 2000 Jan 12;283(2):250-1.

doi: 10.1001/jama.283.2.250.

No abstract available

Comment on

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vézinet F. Descamps D, et al. JAMA. 2000 Jan 12;283(2):205-11. doi: 10.1001/jama.283.2.205. JAMA. 2000. PMID: 10634336 Clinical Trial.
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD. Havlir DV, et al. JAMA. 2000 Jan 12;283(2):229-34. doi: 10.1001/jama.283.2.229. JAMA. 2000. PMID: 10634339